Gilead Sciences' new HIV prevention drug has been added to CVS Health's commercial insurance plans, the drugmaker's CEO ...

Daniel O’Day, Gilead Sciences CEO and chairman, joins 'Squawk Box' to discuss the advances in medicine, what to expect at the ...

Still riding the high of last year’s twice-yearly HIV PrEP approval of lenacapavir as Yeztugo, Gilead Sciences is approaching ...

At a J.P. Morgan media event Tuesday, the Gilead C-suite seemed to be walking on air as they highlighted Yeztugo’s capture of ...

Since my article from October, "What To Expect From Gilead in Q3 2025", Gilead Sciences' stock ( GILD) reached an all-time ...

On January 6, 2026, OncoNano Medicine announced a research collaboration with Gilead Sciences to test its ON-BOARD ...

In the most recent trading session, Gilead Sciences (GILD) closed at $122.59, indicating a +1.23% shift from the previous ...

Pharmaceutical patent protection can be extended when drug companies bring newer products to market before their first patent ...

This was the stock's second consecutive day of gains.

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

If you are wondering whether Gilead Sciences is fairly priced or offering value right now, this article will walk through ...

Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including ...